AtriCure, Inc. (ATRC), a medical device company specializing in the treatment of atrial fibrillation, reported a strong financial performance in the first quarter of 2024. The company's total revenue reached $109 million, marking a 16% increase from the same period in the previous year. A significant uptick in adjusted EBITDA was also observed, nearly 50%.
AtriCure confirmed its yearly revenue forecast to be between $459 million and $466 million, indicating a 15% to 17% growth year-over-year. The company's strategic focus on innovation and market expansion, particularly with the success of its EnCompass Clamp and the introduction of new devices like the AtriClip FLEX Mini and cryoSPHERE Plus, is expected to drive profitability and enhance its market position in the treatment of atrial fibrillation and postoperative pain management.
Key Takeaways
- AtriCure's Q1 2024 revenue increased by 16% year-over-year to $109 million.
- Adjusted EBITDA saw a nearly 50% increase.
- Full-year revenue guidance reaffirmed at $459 million to $466 million, representing 15% to 17% growth.
- The company is focusing on innovation, market expansion, and driving profitability.
- Success highlighted in open ablation franchise and pain management, with new product launches anticipated.
Company Outlook
- AtriCure expects continued growth through innovation and market expansion.
- The company is investing in clinical trials to differentiate its products, such as the LeAAPS trial for AtriClip.
- AtriCure anticipates the successful launch and adoption of the cryoSPHERE Plus and cryoSPHERE Max devices.
Bearish Highlights
- A decline in minimally invasive appendage management products was noted.
- Operating expenses increased by 16.1% due to investments in R&D.
Bullish Highlights
- Strong growth in open ablation and appendage management products in the U.S.
- Pain management sales increased by 15.1%, and minimally invasive ablation sales grew by 27.8%.
- International growth was strong, particularly in European and Asia-Pacific markets.
Misses
- The impact of the LARIAT product on the company's growth was quantified as roughly 50 basis points for the quarter.
Q&A Highlights
- AtriCure is evaluating next steps for the LARIAT product, including a potential stroke trial.
- The company remains confident despite competition and believes in the safety and efficacy of its AtriClip product.
- Discussions around PFA technology and its integration into the product portfolio were positive, with ongoing progress in related programs.
AtriCure's robust financial results for the first quarter of 2024 indicate a strong start to the year. The company's strategic investments in research and development, coupled with its focus on innovation and market expansion, are set to reinforce its leading position in the medical device industry. AtriCure's commitment to driving profitability and cash flow generation, alongside the successful adoption of new products, positions it well for sustained growth in the upcoming quarters.
InvestingPro Insights
AtriCure, Inc. (ATRC) has demonstrated a strong financial performance in the first quarter of 2024, with revenue growth and a significant increase in adjusted EBITDA. To provide further context to the company's financial health and market performance, here are some key metrics and insights from InvestingPro:
InvestingPro Data:
- Market Capitalization: AtriCure's market cap stands at $1.2 billion, showcasing its substantial presence in the medical device market.
- Revenue Growth: The company's revenue for the last twelve months as of Q1 2024 is $414.6 million, with a notable growth rate of 18.7%.
- Gross Profit Margin: AtriCure's gross profit margin remains impressive at 75.26%, indicating strong profitability potential from its sales.
InvestingPro Tips:
- AtriCure has seen a significant return over the last week, with a price total return of 9.51%. This could reflect investor confidence in the company's recent performance and future prospects.
- Despite not paying a dividend, AtriCure's liquid assets exceed its short-term obligations, suggesting financial stability and the ability to invest in growth opportunities.
For readers interested in gaining further insights and tips on AtriCure, InvestingPro offers additional information that might be of value. There are several more InvestingPro Tips available at https://www.investing.com/pro/ATRC, and for those looking to dive deeper into their investment research, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
Full transcript - AtriCure (ATRC) Q1 2024:
Operator: Good afternoon and welcome to AtriCure’s First Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes. And at this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session following prepared remarks from AtriCure’s management. I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory comments.
Marissa Bych: Thank you. By now, you should have received a copy of the earnings press release. If you have not received a copy, please call 513-644-4484 to have one e-mailed to you. Before we begin today, let me remind you that the company’s remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure control, including risks and uncertainties described from time-to-time in AtriCure’s SEC filings. These statements include, but are not limited to financial expectations and guidance, expectations regarding the potential market opportunity for AtriCure’s franchises and growth initiatives, future product approvals, clearances, reimbursement and clinical trial outcomes. AtriCure’s results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statements. Additionally, we refer to non-GAAP financial measures, specifically revenue reported on a constant currency basis, adjusted EBITDA and adjusted loss per share. A reconciliation of these non-GAAP financial measures, with the most directly comparable GAAP measures, is included in our press release, which is available on our website. And with that, I would like to turn the call over to Mike Carrel, President and CEO.
Mike Carrel: Thank you, Marissa. Good afternoon, everyone and thank you for joining us today, I am pleased to report a strong start to 2024 as we expand our global impact on patients with atrial fibrillation and postoperative pain. In the first quarter, we achieved total revenue of $109 million, reflecting 16% growth from the first quarter of 2023, driven by steady demand and activity across our franchises and geographies. In addition, we improved gross margins and expanded profitability with a nearly 50% increase in adjusted EBITDA in the first quarter of 2024 compared to the first quarter of 2023. As we continue efforts to grow adoption across our portfolio, we are reiterating expectations to generate full year 2024 revenue of $459 million to $466 million, reflecting 15% to 17% year-over-year growth. We are also reaffirming our plans to deliver a full year adjusted EBITDA of $26 million to $29 million with annual improvements thereafter. We remain confident in our strategy to invest in innovation and growth, while driving increasing profitability and cash flow generation. As I think about the future of AtriCure, our strong growth outlook is the result of many years of innovation, clinical investments and market development initiatives. As you all know, AtriCure is the leader in the treatment of advanced atrial fibrillation and we are number one in each of our multibillion dollar markets. As we uphold this position, we do not take competitions lightly. We have long anticipated that our success marked by consistent double-digit growth within vastly under-penetrated disease states would invite new entrants into the markets. In fact, we have intentionally executed a strategy that involves market expansion and development activities for over a decade in anticipation of some competition, which we are beginning to see today. We believe competition validates the immense opportunity still ahead for our business. And of course, we expect new market entrants to be able to generate business by entering our markets. We know that physicians try new products. That said, we are confident in our long-term prospects, because we know that competition creates greater therapy awareness and stimulates strong long-term market growth. For example, look at TAVR and percutaneous dependence management markets over the past 15 years. New entrants have helped grow those markets and drive multibillion dollar franchises. Our confidence is also founded in the exceptional quality and safety of our innovative products, which are further supported by compelling clinical outcomes. We will continue to differentiate your care from the field by investing in innovation, which you will see this year through our recent cryoSPHERE Plus launch and upcoming AtriClip FLEX Mini launch, both of which we expect to be game-changing technologies and we will keep investing in market expanding clinical evidence in support of our technology, such as the only stroke trial ever done for concomitant cardiac surgery in our LeAAPS trial. Lastly, one of our greatest long-term differentiators is the deep knowledge and strength of our commercial and education teams. We have over 400 field personnel globally, building and strengthening relationships with cardiac and thoracic surgeons and EPS. We will continue to invest across these differentiators in our business, innovation, clinical science and field expertise to enable AtriCure to remain a market leader. Looking forward, we expect to stay several steps ahead of our peers in the market and market development and expansion. To-date, our investments have culminated in a robust cadence of innovation and the launch of multiple growth drivers of our business. More recently, in our open ablation franchise, we have had tremendous success with our EnCompass Clamp. The EnCompass Clamp leverages the proven technology of our synergy ablation system to provide simpler and faster ablations in open heart procedures. This increased procedure efficiency over legacy solutions continues to drive exceptional adoption of this device and opening up new opportunities for growth. We are pleased to see EnCompass highlighted at the recent AATS meeting in Toronto across many papers and presentations. We are committed to making concomitant treatment to standard of care for patients undergoing cardiac surgery and still see significant opportunity ahead in both pre-op AFib patients and eventually post-op AFib reduction. Building on this we anticipate EU MDR approval and the European launch of the EnCompass Clamp in the back half of 2024 further expanding the impact of this outstanding product. Our founding mission is to advance the treatment of atrial fibrillation, leading to the development of standalone minimally invasive treatments for patients. Our hybrid AF therapy is an important extension of our expertise in effective treatment and is the only approved standalone treatment for longstanding persistent AFib. The evidence is clear that the most effective way to treat those patients is with a combined Epicardial and Endocardial approach, making our hybrid AF therapy complimentary to all catheter based technologies. I am pleased to see the strength of our fourth quarter 2023 results carried into the first quarter of this year resulting in increasing adoption across a growing base of accounts. As we expected, 2024 is shaping up to be a pivotal year for standalone treatment of AFib, with the availability of multiple PFA catheter technologies in the U.S. highlighting this attractive and vastly underserved market. We are finding that physician interest in PFA technology encourages robust conversations on approaches to treating AFib and the varying needs of patients across the spectrum of this progressive disease. Our hybrid approach is complementary to PFA and we believe the focus on more efficient Endocardial ablation is a tailwind for everyone in the market long-term. In fact, we have several customers already using Endocardial PFA catheters in the second stage of their hybrid procedures, further validating our thoughts that PFA is part of a rising tide in this market. As we move through 2024, we remain focused on targeted efforts to support accounts as they develop hybrid AF therapy programs. In addition, we are in the early stages of the launch of our Steerable Epi-Sense device in Europe, providing another catalyst for this franchise in our international markets. Our emphasis on innovation also extends to our appendage management franchise. Over a dozen years ago, we set out to transform the standard of care for patients with atrial fibrillation by offering a safer and more reliable method to exclude the appendage. Today, our AtriClip products are the most widely used appendage management devices in the world, with more than half a million devices sold. Given the strength and longstanding contribution of our AtriClip platform, we understand the competitive dynamics in this market are top of mind for investors. However, we are pleased to continue driving healthy adoption in this business marked by over 15% growth in our U.S. open appendage management business in the first quarter and record sales of our AtriClip Flex (NASDAQ:FLEX) V device, even in the presence of competitive device trialing. We are all already seeing the availability of the competitive device yield in-depth discussions on treating the appendage allowing us to highlight the advantages of our AtriClip technology. Over the long-term, we expect this to promote therapy awareness in ways that we could not do on our own. In the short-term, we are ready to compete and remain focused on delivering differentiated solutions. To that end, we are preparing for another significant innovation in this market with our AtriClip FLEX Mini device, which is on track for FDA clearance and commercial launch later this year. The AtriClip FLEX Mini builds on the solid foundation of our AtriClip technology known for ease-of-use, unparalleled safety, and outstanding closure results with a substantially smaller profile in this new device. We also view our market opportunity for appendage management as multiples of where we began dozens of years ago – a dozen years ago. The investment in our LeAAPS clinical trial has the potential to dramatically expand the use of the AtriClip devices as the standard of care for all patients undergoing cardiac surgery, which represents over 1.5 million patients per year globally. The LeAAPS clinical trial is investigating the use of the AtriClip products in patients without preoperative AFib diagnosis, seeking to demonstrate a clinically meaningful reduction in ischemic and systemic arterial embolism. If successful, this massive clinical trial along with existing robust clinical evidence would further separate our products from all other surgical left atrial appendage management devices. Enrollment in the LeAAPS clinical trial has continued rapidly, with almost 2,300 enrollments today driven by strong demand for patient inclusion across 77 sites in the U.S. and Canada. We anticipate the first patient enrollment in our European sites in the coming weeks and we now expect to complete full enrollment of 6,500 patients by the middle of 2025. Beyond our offerings in AFib, we have been successful in creating and expanding our pain management franchise, where our cryoSPHERE product line provides temporary relief from postoperative pain. Since launching in 2019, adoption of the cryoSPHERE probe has been remarkable with over 60,000 Cryo Nerve Block procedures performed to-date. The momentum behind commercial adoption of the cryoSPHERE probe speaks to the meaningful reduction in pain patients experience following thoracic surgery. As this therapy continues to grow, we are making investments in clinical data to support a comprehensive value proposition for both patients and physicians. At the same time, we are actively improving our current technology to advance therapy adoption. Recently, we announced the limited launch of our cryoSPHERE Plus device, which features new insulation technology to reduce freeze times by 25%. The limited launch is progressing well. The feedback has been excellent and we remain on track for a full scale launch by the end of this quarter. As cryoSPHERE Plus makes its debut, we are completing studies to show the benefits of our new cryoSPHERE Max probe, which incorporates this new insulation technology and features a larger ball tip. We expect the cryoSPHERE Max probe to show even further reduction in ablation and procedure time and expect to launch the cryoSPHERE Max probe late in 2024. We are confident that the improvements we are making will strengthen the case for adoption and an expanded set of use cases, including the sternotomy market. As we innovate and execute against our current market opportunity, we are researching additional market expanding applications for Cryo Nerve Block therapy and look forward to updating you on our progress. In closing, I would like to reiterate my earlier comments. We have made investments across multiple growth vectors that will enable AtriCure to remain a market leader and we expect to stay several steps ahead of peers in the market development and expansion. Over the past decade, our company has consistently delivered outstanding growth even in the context of pressure in different markets. Looking forward, we remain positioned to penetrate each of our markets meaningfully and sustainably driving durable growth and leverage throughout our organization. I believe the future of AtriCure is even more compelling now than ever before, with new market entrants validating this position. Therefore, as we look forward into 2024, we remain focused on expanding the reach of our solutions for patients with advanced forms of AFib, managing the left atrial appendage and patients undergoing cardiac surgery and reducing postoperative pain. We are also eager to launch several new products across our markets and expand our clinical research initiatives, all while continuing our efforts to improve profitability in our business. And with that, I will turn the call over to Angie Wirick, our Chief Financial Officer. Angie?
Angie Wirick: Thank you, Mike. Our first quarter 2024 worldwide revenue of $108.9 million increased 16.4% on a reported basis and 16.3% on a constant currency basis when compared to the first quarter of 2023. We saw strong growth across franchises and geographies demonstrating the diversified growth drivers of our business in each of our markets globally. Sequentially, worldwide sales grew $2.3 million or 2.2% over the fourth quarter of 2023. First quarter 2024 U.S. revenue was $90.2 million, a 15.4% increase from the first quarter of 2023. Open ablation product sales were $29.3 million compared to $25.1 million, up 16.5% over the first quarter 2023 and propelled by ongoing adoption of our EnCompass Clamp across both new and existing accounts. U.S. sales of appendage management products were $35.9 million, up 11% over the first quarter of 2023. We saw robust growth in our AtriClip Flex V device, driving our open appendage management products to an overall growth rate of approximately 15.4%. As Mike noted in his comments, our strong first quarter growth in open appendage management products is against the backdrop that included accounts choosing to trial the Medtronic (NYSE:MDT) device. However, our appendage management franchise revenue saw pressure from a decline in our minimally invasive appendage management products, primarily from a reduction in LARIAT system sales, where we have a very limited base of users and following an outstanding fourth quarter growth in our MIS AtriClip products. Pain management sales were $12.7 million, up 15.1% over the first quarter of 2023 and with limited revenue contribution from our new cryoSPHERE Plus probe. Finally, minimally invasive ablation sales were $12.3 million, up 27.8% over the first quarter of 2023. Similar to the end of 2023, our results this quarter reflect an increasing demand for our hybrid AF therapy, with more accounts adopting this treatment for advanced AFib patients. International revenue totaled $18.6 million, up 21.5% on a reported basis and up 21.1% on a constant currency basis as compared to the first quarter of 2023. European sales accounted for $11.3 million up 20.7% and Asia-Pacific and other international markets accounted for $7.3 million in international sales, up 22.9%. We are excited by the continued strength of our international business across franchises and geographies and see pathways for accelerated growth to extend throughout 2024. Gross margin for the first quarter 2024 was 74.7%, up 21 basis points from the first quarter of 2023. The increase was driven primarily by both product and geographic mix along with operational efficiencies. Now, moving on to operating expenses for the quarter for comparability of operating costs, my remarks will exclude the $4 million gain on legal settlement recorded as an offset to SG&A in the first quarter of 2023. Operating expenses increased $12.8 million or 16.1% from $79.4 million in the first quarter of 2023 to $92.2 million in the first quarter of 2024. Overall, the change was a result of our continued investments in research and development activities, which increased approximately 29% from the first quarter 2023 reflecting robust enrollment in our LeAAPS clinical trial and progress on several research and product development initiatives. We saw leverage within SG&A as expenses increased by approximately 13% from the first quarter of 2023. And as we navigate the remainder of 2024, we will prioritize investments in research and development to ensure our future with an enhanced pipeline of products and clinical evidence balanced with our commitment to realize increasing economies of scale to expand profitability. Now turning to the bottom line, we drove adjusted EBITDA $2.8 million for the first quarter 2024 compared to adjusted EBITDA $1.9 million for the first quarter 2023 for an increase of approximately 46%. Our loss per share was $0.28 in the first quarter 2024 compared to a loss per share $0.14 in the first quarter 2023. While the adjusted loss per share each period was $0.25, and $0.23 respectively. We ended the first quarter with $106 million in cash in investments reflecting our normal pattern of a heavy burn, heavy first quarter burn driven by share vesting, variable compensation payments and operational needs. We expect to generate positive cash flows for the remainder of 2024, resulting in a modest overall burn for the year, which is consistent with our guidance earlier this year. We remain in a very solid position with our balance sheet to fund the current and future operating needs of the business. And now closing with our outlook for 2024, as Mike mentioned, we are reiterating our expectations for full year revenue of $459 million to $466 million, reflecting growth of 15% to 17% over the full year 2023. Underlying procedure trends, and the operating environment remains stable in our key markets worldwide. Therefore, we expect to see sequential revenue growth from the first to second quarter that is in-line with historical seasonality in our business. In other words, we expect to see mid-single digit to upper single digit growth on a sequential basis. From a margin perspective, we continue to expect 2024 gross margin to be in-line with 2023 gross margin, with the potential for varying impacts from cost savings initiatives, product and geographic mix. As I stated earlier in my comments and on previous calls, our primary focus with capital allocation is to incubate the next set of growth drivers for AtriCure. Therefore, we expect to maintain R&D as a percentage of revenue at roughly 19% to 20% in 2024. Our spending across SG&A will moderate in proportion to revenue as the year progresses, providing leverage and sustained improvement to profitability. With this in mind, we are reiterating our expectations for full year 2024 adjusted EBITDA of $26 million to $29 million, translating to an adjusted loss per share of approximately $0.74 to $0.82. We expect the remaining improvement to full year 2024 adjusted EBITDA over a full year 2023 will occur in the third and fourth quarters of 2024 largely based on timing and expansion of R&D costs from the comparable quarters in 2023. Overall, the first quarter 2024 results demonstrate that the strength and depth of our product portfolio, we are extremely pleased with our performance and the advancements of many impactful initiatives across the globe, along with increasing profitability in 2024. Now, I will turn the call back to Mike.
Mike Carrel: Thank you, Angie. We began 2024 on a solid footing across our business with strong growth on both top and bottom line while delivering on many key product and clinical milestones, which will drive growth for years to come. I would like to thank the entire AtriCure for your commitment to our patient first mission. Continue to live our values every day, as we work together to build an even brighter future for our business. We have the unique opportunity to both advance and further expand our markets as we work to heal the lives of those affected by Afib and pain after surgery. And with that, I’ll turn it over the operator for questions.
Operator: [Operator Instructions] Our first question comes from Robbie Marcus with JPMorgan. Your line is open.
Robbie Marcus: Great. Thanks for taking the question. Congrats on a good quarter here. Maybe I could start on the guidance Epi revenue versus the [indiscernible] by $2 million looks like missed EBITDA just slightly by a $1 million yet. Kept guidance on the top line reiterated for the year. So maybe just walk us through the thought process there and how you’re thinking about the guidance and in light of the first quarter. Thanks.
Angie Wirick: Thanks, Robbie. I’d say just it’s still pretty early in the year and while we’re really pleased with the results of the first quarter, felt like it was prudent to keep the guide in place. Mike walk through several new product introductions in his comments as well as, increasing penetration of the market throughout the year. As really the big growth drivers as we operate through the remainder of 2024. And we’re seeing really robust momentum in our international business as well, which gives us good confidence in the ability to deliver and perform for the remainder of the year. So just felt like it was early in the year and prudent to keep that the guide where we were at.
Robbie Marcus: Got it. You talked a bit about AtriClip and in the competitor, out in the market, I was hoping you could go into that a little more. When I look at the results, it’s the one-line item where you didn’t beat in the first quarter. There is obviously a lot of concern out in the market. So I was hoping you could walk through your expectations for that line item for the rest of the year, and what you’re seeing competitively out in the market. Thanks a lot.
Mike Carrel: Yes, I think we’re going to tag team that one, Robbie. So appreciate the question. I know that it’s top of mind for a lot of investors. I’ll start with just kind of what we’re seeing out in the field. As I mentioned in my comments, we definitely see the competition and a lot of sites, trialing the competition out there. We’re not seeing any kind of massive shift in any kind of market share from that standpoint, but we definitely see them in the field. Our team has done a really nice job of understanding what’s happening at every one of the accounts, but they’ve also got relationships that are a variety of different accounts around the country. That being said, as I mentioned in my comments, I feel really confident in both our product that exists today, which we think is by far the best in the market. It’s a great product that has been proven from both a safety and efficacy standpoint, I believe most customers understand and believe that, but they’re going to try it. I mean, they’re human beings, physicians like to try new things. And we definitely see sites trying out the new product, because they want to kind of see what else is on the market. As I mentioned in my comments, it’s really important to understand that I think this drives great conversation, they’re going to get some market share on it. Obviously, we understand that, but it drives discussion about managing the appendage, it drives discussion about the guidelines that just came out from both STS and AHA, and ACC recently an era over in Europe that say, you must treat the appendage every time someone has Afib. And obviously, there’s a great way to treat the appendage with the AtriClip. So it drives a really good conversation around treatment of the appendage, and then leads into the conversation around. Well, we’ve got this trial, and we’re getting sites up and running. As you heard, we’ve got 77 sites up and running on our LeAAPS trial from that standpoint. So yes, we’re seeing competition out there. We definitely see them in the field. And we see people trying – trialing their product. But overall, I think that we’re in a really good position, you saw our numbers with over 15% growth on our open part of our business. I’ll let Angie talk a little bit more maybe about kind of how we’re projecting and looking at the rest of the year as well.
Angie Wirick: Yes, so our guidance for the full company is a growth rate of 15% to 17% for the full year. I think that being said, we understand that there may be some fluctuations in different areas. But as a business over a very long track record, we’ve been able to deliver high growth from the business overall, in our expectations, where we started the year that each component of the business, each of our franchises would start to converge around that corporate growth rate, we still feel like that is intact at this point in time. I think you know, very different from our expectations last year in 2023, where we knew that there would be some areas, some particular franchises that had very outsized growth, and then, others that may be behind, we still like still each area of the business converging around that kind of overall corporate growth rate. So, the pressure that you see in the U.S. appendage management number in the first quarter just to frame this up, about 75% of our U.S. appendage management revenue is in our open, open CEASE study. The remaining 25% is in a minimally invasive setting. And we’re still seeing nice and strong attachment to our hybrid procedures. But where we’ve got the competitive device, like Mike said, we grew 15.4% in the first quarter, and saw really outsized pressure from a reduction in our LARIAT system revenue as well as some transition on our MIS AtriClip revenue, which brought the overall U.S. appendage management revenue growth rate down for the quarter.
Robbie Marcus: Appreciate it. Thanks a lot.
Operator: Thank you [Operator Instructions]. And our next question comes from William Plovanic with Canaccord Genuity. Your line is open.
William Plovanic: Yes, great. Thanks for taking my question. And good evening. I was wondering, just a little bit more on the LARIAT. I think that’s been a business. Have you discontinued that product in the U.S.? Is that going away? Or is that a one quarter kind of deal and then just competitively, have you seen any change in pricing or bundling strategy in terms of the penetrator device? And then, just since we’re on that, Mike, how do you think about long-term growth in the LA market today is just going to be a 50%, grower and 20%, 15% growth, 20% growth, and I’m talking about the U.S.?
Mike Carrel: I’ll start on the first one. So because I think there is three different questions in there. So the first one was about LARIAT, as you know, back several years ago, when we did the readout on the trial, while the device actually worked incredibly well for closure, it actually had better closure than any percutaneous device on the market today, and also had a great safety record in the trial. And if you recall, is a 600 patient trial, it did not meet the endpoint of reducing Afib, it reduced Afib by 4.3%. And we needed to hit about 8% in order to win the trial and have superiority. So as a result, the product has still been on the market under the 510(k) that was originally on people continue to use it but we weren’t adding any net new sites. And so what you’re seeing now with LARIAT is we’re trying to evaluate what are next steps, we know this product is an exceptional product, it works very well. It is a product that does not get left in the bloodstream, like you do on the other percutaneous occluder market. But we’ve got to consider what are our next steps with that product, and likely would have to run a stroke trial. And I’m not saying we are going to but that would have to be the logical thing for someone to consider with it at some point in time, we’re not shutting it down because it is being used. That being said, the pressure is, as you’ve seen in this market, it’s not a lot of revenue. But as you’ve seen in this market, you’ve got new products coming on that are in trials. So there was a product called conformal. And then also the laminar just came out. So many sites are now getting involved in new trials on the new devices that are coming out. And my – our suspicion is that you’re seeing a little bit of pressure on that, because it’s not a lot and the sites that were using our products tended to be the more advanced sites that are out there, that would tend to be part of some trials like that. So we think that’s kind of where maybe some of that pressure is happening on malaria products. We’re not promoting it, we’re not pushing the market. But we have not shut it down, either. As it relates to kind of the – kind of market dynamics, we’re seeing good consistent pricing in the market. And feel really good about that. From that standpoint. We think it’s a – it makes a lot of sense from that standpoint. And then finally, as we look at the long-term rates for appendage management, I’m not going to give a specific number. But there’s a reason we’re running the LeAAPS trial, the LeAAPS trial is about close to tripling, maybe quadrupling the size of the overall market for people that can get their appendage managed that full 1 million patients around the globe that are undergoing cardiac surgery, we believe the LeAAPS trial will demonstrate if you put an AtriClip on those patients prophylactically or even when they’re in Afib, prophylactically in the trial, that you are going to reduce their stroke rate and their incidence of strokes. And we think that will be a big global trend that will happen once that product reads out. That should longer-term drive significant growth on the appendage management business for a very long period of time. And so without getting a specific number, we do see that this market is less than 20% penetrated in the U.S. when you kind of calculate all those patients, and less than really between about 5% and 10% on a global basis. So a long way to go without getting a specific growth rate, though.
William Plovanic: Great, and then a follow-up if I could on EPi-Sense, is PFA been a distraction, the EPi-Sense number was great. So the question we’ve been getting asked from investors is, is PFA going to be a distraction is OCPs adopt PFA. And it makes it harder for you to kind of get in there and get those new accounts because they’re focused on getting trained on other technologies. And then on PFA, what product are you targeting, first with PFA in your own portfolio? And thanks for taking my questions.
Mike Carrel: Sure. As relates to the catheter base, PFAs, and the excitement that’s out there, as I mentioned in my comments, we think it’s actually engaging conversations, it’s allowing us to have conversations that EPi that maybe we weren’t having before, we’ve got several sites, as I mentioned, that are now actually using PFA in the conversion procedure. So it’s not actually having an impact on us in terms of getting and setting up new sites, or any kind of major distraction from that standpoint, it really actually drives good discussion and conversation around well, how would PFA work in a hybrid type setting? And so there’s a lot of discussion about that. And so, we believe that discussion and awareness is good. Remember, PFA is an efficiency gain more than anything else, when you look at the data and the results from all those companies, CONVERGE is an efficiency gain in terms of you reduce the time that someone has to do an ablation when they go in? So you’ve got double efficiency gains, people recognize the importance of that. And that’s actually been a lot and a big part of the conversation relative to that. I know there was a second part of the conversation
William Plovanic: It was [indiscernible], for your own portfolio, what’s the first product?
Mike Carrel: Yes, I mean, we think PFA can fit really well into every one of our technologies, very well as an option for people to utilize. As we’ve mentioned on this call before, we’ve definitely got programs underway, and we are making really good progress on that front, and it would be across pretty much our entire portfolio of products.
Operator: Thank you. [Operator Instructions] Our next question comes from Rick Wise with Stifel. Your line is open.
Unidentified Analyst: Hi, Mike. Hi, Angie, this is John on for Rick today. First question, just curious about pricing the quarter. And also in the year ahead, you have several product launches, just curious how it might have factored into growth here and how you’re looking at it for the rest of the year?
Angie Wirick: Hi, John, when you think about a couple of the product launches that we outlined on the call, I think we’ve said, the cryoSPHERE plus the newest technology, that we’re in the process of a limited launch currently, in our pain management business, we would expect that to launch at similar pricing to the device that’s on the market. Today, there’s a time savings benefited, we do think that most accounts will migrate over to this and there’s actually a cost savings benefit to the company, it’s a better gross margin profile. But keeping the price the same on that so not going to be a big driver of growth throughout the year, I’d say a AtriClip Flex Mini, which would be kind of next step in terms of the launch, to be determined that, at a future date warmer closer to the launch on that the way that we’re thinking about this, though, from how that factored into the guide is just looking for the impact from a volume perspective and not an uplift on a pricing perspective. With a couple of the products in our European markets where we’ve gotten premiums in the U.S., the strategy would be the same when we launched the EnCompass clamp in Europe, it would be at a higher price than our existing devices. So that’s been factored in to kind of the outlook, again, minimal quantities in 2024, more impactful in 2025. But that has been factored into the overall guide. So taking a step back, when you look at the quality of growth for 2024, we believe most of this is driven by just sheer volume growth as we continue to penetrate each of our markets.
Unidentified Analyst: Great, that’s helpful. And just to follow-up, you talked about starting up the first LeAAPS site in Europe. And I was just curious, you saw pretty strong growth again, o-U.S. in the appendage management business. I’m just curious, maybe how LeAAPS can help get the O-U.S. business potentially growing faster, more sites interested? Just sort of any thoughts there on dependency management outside the U.S.? Thanks for taking the questions.
Mike Carrel: I think, when we think about long-term, the impact of LeAAPS, the reason we’re doing a global trial, and including both Europe and Asia in the trial, trying to get them up and running fast because it’s enrolled so fast in the U.S. is because we do want to make the standard of care changes everywhere around the globe. It’s that’s what this trial is meant to be. It’s one of the reasons to trial so large. And so we’re really excited about getting Europe up and running now and hopefully within the next 3 to 6 months getting some sites in Asia as well. So that can be truly an international trial on that front. And we believe that’s going to change adoption rates around the globe. As I mentioned, it’s only like 5% penetrated around the globe. And so if we can improve stroke reduction in this patient population, that’s obviously a significant benefit for society. And for those patients, which we believe can change payer practices in countries throughout the world. And that is one of the reasons that we’re doing that trial. So I do think that’s going to be a critical piece for us to change care is the LeAAPS trial overall, in the short-term what we’re seeing is just a recognition with all the guideline changes that you’ve seen. First, the guidelines in the U.S. and then now era just came out recently where they made it a Class 1A guideline that you must manage the appendage, it’s basically telling everybody that they need to increase that I believe that guideline changes that we’ve seen over the last 4 months, will probably have a more dramatic effect on our business o-U.S. just because there’s so lowly penetrated at this point in time. It takes time though, because they’ve got to work out reimbursement by country and things like that. But I do believe that there’s the potential to have some impact based on those guideline changes.
Unidentified Analyst: Thanks very helpful.
Operator: Thank you. [Operator Instructions] Our next question comes from Marie Thibault with BTIG. Your line is open.
Marie Thibault: Hi, good evening, and thanks for taking the questions. Want to revisit the LARIAT and AtriClip discussion just to try to triangulate some of the numbers you offered us. It looks like LARIAT and minimally invasive AtriClip were flat growth year-over-year at about $9 million of the U.S. appendage management revenue this quarter. And then AtriClip in the open setting, which is where we’re seeing the competition was about $27 million which grew 15.5% you said, to those numbers sound about right to you? And then secondly, is that the right way to think about kind of a similar breakdown and growth trend for those two parts for the rest of the year? Mid-teens in the open AtriClip and then flat and other appendage management, just want to make sure that we understand some of those puts and takes.
Angie Wirick: Marie, you are directionally correct on the revenue components, the open AtriClip business, just under $28 million in the MIS appendage management business, a little over $8 million for the quarter at the 35 point close to $36 million for the quarter. We did actually see our MIS appendage management business go down. That is largely driven by the LARIAT product or Q1 of last year was kind of an outsized quarter and we have just very few customers, so activity within a pretty small base of customers can skew the results there and following up a pretty strong fourth quarter for our MIS AtriClip. We saw a bit of softness in that area of the business in the first quarter. I would say longer term, we would expect LARIAT to not be a big driver behind fluctuations either to the positive or negative just based on the comparable quarters in 2023. And when we think about our MIS AtriClip business, we are still seeing really strong attachment in our hybrid procedures and would expect as you continue to see strong results within our MIS ablation business for that to be a bit of a carry. But in the longer term, I think you will see probably more of what we have seen in the past from that particular franchise, meaning our appendage management franchise, the growth typically has been driven more by the open side of the business. But I think that there is a pathway given the adoption and trends that we are seeing in MIS ablation to see an uplift on our MSH put them in the future.
Marie Thibault: Okay. That’s really helpful, Angie. Thank you. And then I want to ask the open ablation that that segment was again really strong here in the U.S. I think as of the latest about half or more of it was of the U.S business was EnCompass Clamp. Can you give us an update on the pace of adoption of that new ish system? It does seem like there is more runway ahead, and I recall there was some price uplift as well. But just wondering where you are in the adoption curve and what growth drivers are there for the volume side? Thanks.
Angie Wirick: Alright. So, another great product here with the EnCompass Clamp, that you are still a little bit under 50% of the revenue in the first quarter. And we think we are still in pretty early innings when it comes to adoption our EnCompass Clamp for the quarter over 450 accounts for users of that device, up from the fourth quarter and up from each quarter in 2023. We think about the kind of number of accounts that we have got in the U.S in terms of users on our open side, still plenty of accounts to bring this to and I would say even with an existing accounts plenty of doctors, surgeons that could be using the product as well. So, that’s what we are really targeting in terms of our efforts on the EnCompass Clamp roll out. This – the open chest market, so our cardiac surgery market still remains vastly underpenetrated. So, while we have seen great traction with this device, we sit here today and say there is still plenty of room to grow and are really targeting on new users and making sure that adoption happens for every patient that’s on the table.
Marie Thibault: Thank you.
Operator: Thank you. [Operator Instructions] Our next question comes from Matthew O’Brien with Piper Sandler. Your line is open.
Unidentified Analyst: Hi. This is Sam [ph]. Your question, I guess first, if we could ask a little bit more about the guidance and what that implies for the rest of the year. And then also maybe what we can expect sequentially throughout the rest of 2024?
Angie Wirick: Hey, Sam. We caught the back part of your question. Can you repeat the first part?
Unidentified Analyst: Sure. Yes. I guess I am just asking about what guidance implies for the rest of the year.
Angie Wirick: Oh. Okay. Sorry. Thanks. Thanks for repeating that. Like we said in the prepared comments, our expectation is just given, I would say the stability that we are seeing in end user markets both in the U.S and internationally, that we would expect some of the historical patterns that you have seen in the business in the past to be present, when you think about sequential growth. So, that means kind of mid to upper-single digit growth from the first quarter to the second quarter of 2024 and again reaffirming the guidance for the full year of the 15% to 17%, driven by that the full business. And as we think through that and think through those numbers, I think understand the interest in each of the components of the business and how that they will drive, I think we have been, you are aware that the company overall of the different growth drivers has been able to promote very robust growth of AtriCure and deliver in both meet and exceed our guidance as we operate throughout the year. And we have the same expectations as we think through kind of the operations of the remainder of the year.
Unidentified Analyst: Great. Thank you. And then just one more on the appendage management business also, how long do you expect this trialing to last and I know that ultimately you think this will help grow the market? When do you think you could see that kick in?
Mike Carrel: And I think that trialing is going to continue on. I mean that there we have got a competitor in the market as we mentioned. And as everybody is well aware of, they are going to be in the market, people are going to try it and are going to keep using it. And they are going to have some market share relative to that. But as we have talked about, we did, we grew 15% in one of our largest franchises or 15.4% in the U.S. And we haven’t even kicked in a new product that’s going to be introduced later on the year and obviously LeAAPS coming out kind of in subsequent years after that and future product iterations that we have. So, we think that you are already starting to see a little bit of the benefit, because they did get some share this quarter and we still saw some solid robust growth relative to that. So, whether or not we are going to see kind of uptick on that, we are not going to put that out there right now. I do think that the LeAAPS trial long-term plus the continued innovation will drive this market out for a long period of time.
Unidentified Analyst: Great. Thank you.
Operator: Thank you. [Operator Instructions] Our next question comes from Danielle Antalffy with UBS. Your line is open.
Danielle Antalffy: Hey guys. Thanks so much for taking the question. Just to Mike, you are going to be so sick of talking about AtriClip after this call. But I am going to ask one more question here and I would love a little bit if you could more color on where you see the most adoption, I mean I know Medtronic has barely any presence on the open ablation side of things. But they do have some legacy users there. Is it adoption in open procedures where an AtriCure ablation is being done, like is it broad basis trialing or is it more specific to one area versus one product than another?
Mike Carrel: And maybe to be clear, I mean we are trying everywhere. I mean it’s all over the country. It’s so you are definitely seeing them in markets and in almost every market around the country. I would gather that most of it has to do with good relationships. Medtronic has some good relationships that accounts, that’s probably where they have targeted first and gotten into it in terms of where we have noticed. But of course it’s definitely happening in procedures where AtriCure has gotten ablation going on and then they are testing out and using the Medtronic product on that front. So, we definitely see it there, but it’s happening everywhere and they have done a full launch on it. They have talked about it, they have marketed to it and so we see them all across the country.
Danielle Antalffy: Okay. Got it. So, it doesn’t sound like there is any difference in your uses and procedures being done where an AtriCure open ablation also being done, it sounds like you are seeing some stock pick-up expenditure in that procedure as well.
Mike Carrel: That does happen for sure, yes.
Danielle Antalffy: Yes. Okay. Alright. And one quick follow-up on [indiscernible], I mean another really good quarter. So, just trying to get a sense of how much of this is new center add versus same-store sales. I think you guys have talked about new center adds sort of not as much of a focus, more focused on driving adoption higher at existing centers. Can you talk about whether that continues, are you seeing more new centers come onboard, any color there, that would be great. Thanks so much.
Angie Wirick: Yes. Danielle, I would say across the board, the new centers add very little revenue to any individual quarter and that to a tee for each of the franchises. When I think about each area of the business, we do continue to add accounts. I would say in some places like our pain management business at a much faster pace than other areas like our EPi-Sense accounts. That being said, we are adding new accounts just at a slower pace. So, the revenue that you are seeing in the first quarter 2024 is largely from existing customers with some incremental pieces from newer accounts that over time will become much higher revenue contribution.
Danielle Antalffy: Thank you.
Operator: Thank you. [Operator Instructions] Our next question comes from Daniel Stauder with Citizens JMP. Your line is open.
Daniel Stauder: Yes. Thanks. So, it’s my first one just on international sales. EnCompass Clamp has European launch later this year and then I think you said EPi-Sense also be introduced internationally. And you are coming off a strong growth year outside the U.S 2023, so just wanted to ask, how should we be thinking about international sales contributions this year, at a high level as we model and throughout the year?
Angie Wirick: Yes. Daniel, when we look at our international business, just really pleased with the developments and the activities of that team over the past several years. We are leading to an accelerated growth rate. You saw that throughout 2023 and that repeated in this first quarter to start 2024. Our expectations are both of those products steerable EPi-Sense device. We do have the original EPi-Sense device on the market. But the steerable device, the EPi-Sense ST is right now in the process of a launch. We expect that to be a nice catalyst for that business where they just have done very much fewer converge procedures, so we are hoping that that’s a nice catalyst for that area of the business. And then the EnCompass Clamp, our hope is that that’s much later in 2024, once we have been through EUMDR approval, and ready to launch on that. But our hope is that’s a really solid catalyst for our open ablation business, much like you have seen here in the U.S. I think we are all aware that pricing, a little bit more sensitivity in the international markets, but I think ease of use of the device and the differentiated technology give us a lot of confidence that this is going to be a really great product for that market. So, longer term, we have said look, U.S and international generally at the same growth rates, I think you have got a lot of reasons based on historical performance and some of the catalysts in our international markets to say that might be bigger leading edge of growth.
Daniel Stauder: Great. And then just one follow-up on the pain management side, you talked about the plus and the max helping with the time aspect, but just wanted to ask more about progress in gaining direct reimbursement. I know there is a handful of studies in this area, but what your mind moves the needle in terms of gaining reimbursement for these products? Thanks.
Mike Carrel: I think the key to reimbursement on pain management is clinical data. Clinical evidence showing a combination of cost savings in some way, whether it’s length of stay or fewer calls or return visits back to the ER and hospital that happened a lot in some of these cases, because of the pain that somebody experiences two weeks, three weeks, four weeks out. That is quite frankly really helped out by the use of our Cryo Nerve Block. In addition to that, if there are studies that are being done that kind of demonstrate the true reduction in opioid use afterwards, we have seen some studies, but I think you have got to have enough studies that are out there. We have funded a lot of these studies. It’s going to take some time, but we saw that in cardiac surgery, it took us about 8 years and I know that sounds like a really long time. But through papers that were written over time that we are studying to show the benefits of treating, they said at the time of cardiac surgery. You are now starting to see CMS over the last 2 years, increased reimbursement quite dramatically for that. And I believe the same thing will happen eventually for pain management, we just need a lot more studies to be done and we are helping to fund a lot of those.
Daniel Stauder: Great. Thank you very much.
Operator: Thank you. [Operator Instructions] Our next question comes from Mike Matson (NYSE:MATX) with Needham & Company. Your line is open.
Mike Matson: Yes. Thanks. So, Mike, when you were at our conference a few weeks ago, you mentioned that you were working on launching or developing, I guess clamps that would use PFA for open ablation. I just wanted to see if you could give us an update on that kind of any timing? And what would be required? Is it a new clamp or is it just a new generator?
Mike Carrel: Yes. As we did mention briefly, we have been working on work in that particular area. It’s got a combination of generator and clamp and quite frankly other technologies as well to be distributed across our product line. No update on timing. I mean we believe that we need to have all of the energy sources available for our customers. And so we think PFA is an exciting new technology that we are going to make sure that we have incorporated into the procedures that we have basically been a part of for many, many years. Now, it’s too early to give any kind of specific updates on what that looks like a product like that’s going to have to go through some clinical work and regulatory work, etcetera. So, that there is definitely work to be done on that front. But from a product standpoint, we have made a lot of progress.
Mike Matson: Okay. Thanks. And then just on the LeAAPS trial, so obviously doing really well and rolling pretty fast. Do you – when and if it’s successful, do you think that it would create kind of a class effect and benefit. Any of the products clips that are out there or do you think it would really be just specific to you AtriClip? I mean I know you would be the one with the indication. But for stroke or I guess prophylactic use, but, do you think that would kind of help out your competitor to any degree as well?
Mike Carrel: Well, I mean to your point and let’s start, I mean we are investing in this trial, because we believe it’s the right thing to do for patient care for the long-term. And number one, it’s going to be our product exclusively used. So, it’s going to be a 6,500-patient trial. The product is going to be used to get the stroke label is going to be the AtriClip. That’s what we will have the stroke label, our competitor products would not have that. Is that a differentiator, absolutely. There is no question about it that once we are able to get that kind of level, it should be a differentiator. However, if somebody else has a product on the market and somebody feels like they want to use that product and believe that that product has some benefits to it, I am sure there will be some level of a class effect on that point. At that point, we are talking about 1.5 million patients around the globe that will be using some sort of clip just in cardiac surgery, not including what’s going to be used in any other area. So, to me, obviously you are going to have competition. I mentioned it earlier, when you build big multibillion dollar markets, you are going to have competition and competition is going to hit some level of share during that period of time. We saw it in TAVR. We saw it in the occlusion market. And in both of those cases they have created multibillion dollar markets. And the competition has been there as well and then it becomes who has got the best clinical evidence, who has got the best product in the market.
Mike Matson: Okay. Thank you.
Operator: Thank you. [Operator Instructions] And our next question comes from Suraj Kalia with Oppenheimer. Your line is open.
Suraj Kalia: Mike, Angie, can you hear me, alright?
Angie Wirick: We can hear you.
Suraj Kalia: Perfect. So, Mike, couple of questions, your way one is in terms of the PFA clamp, for open I understand, but can you walk us through the, I believe in your prepared remarks, you talked about the complementary, you were seeing with your existing clamps that PFA catheters. In long standing persistent AF, PFA, I believe they have just started clinical trials, right? So, we don’t have any data yet and I am curious if you could just kind of thread the needle for us as to how it is complementary in terms of the clamp and PFA catheters.
Mike Carrel: The complementary aspect is think about PFA catheter today, if it’s going to do the pulmonary veins, that’s exactly what is being used and has been used with CONVERGE. When you do a CONVERGE procedure and you do a lot of the back wall ablation, in our trial, it was RF, in our upcoming trial and a lot of the usage today it’s with cryo doing just the PDI on it and kind of finishing up the veins. PFA can be used very similar to that, so the EPs may choose to use that instead of using their cryo or their RF, when they complement it with what they are getting from the epicardial surface approach that we bring to the table. We absolutely believe and has been showing clinical trial after clinical trial, but when you add epicardial to endocardial, you get a much more durable long lasting lesion. And you get almost double the success rates as a result of that. And so you are definitely you are starting to see people begin to use that both in Europe and in the U.S to complement what they are doing. They are just kind of using that instead of some other capital that they would have otherwise used when they were doing the endocardial portion.
Suraj Kalia: So, Mike, just to be clear and forgive me for belaboring this, the argument being made is that PFA doesn’t achieve transmuralality.
Mike Carrel: No, no, I am not saying PFA, it is what I am suggesting is, PFA works incredibly well and we have seen the data from the results, in these and most of them have been for the pulmonary veins. And so CONVERGE, there is a really good back wall ablation to areas that catheters don’t typically get to or get to very well. And that they can’t get transmural for a variety of reasons, some of which is the safety reasons, some of which is that there are fat pads and other things, and there are differences between the epicardial surface and the endocardial surface where the epi and the endo together getting much better results. The endocardial products do very well during the pulmonary veins, as you well know, Suraj. And so I am not saying that they don’t get transmural, they get transmural in the veins for sure, and we have seen that and I think you have seen that with the PFA technology that they have been doing a very good job on the veins for sure.
Suraj Kalia: Got it. And Mike, I know, forgive me, I have to ask, did you quantify the impact of LARIAT in the quarter? Obviously, LARIAT is MIS, you have AtriClip MIS, you have AtriClip Open and then AtriCure Open [ph]. You are just kind of quantifying these two buckets, what impact you all saw from, let’s say, from AtriCure for Open and LARIAT for MIS? Thank you for taking my questions.
Angie Wirick: Yes. Suraj, on the LARIAT question, it’s roughly 50 basis points of growth impact for the company overall for the quarter, when you exclude LARIAT. Again, it was an outsized kind of Q1 in 2023, we saw decline throughout 2023. And just a very soft first quarter, again a very limited number of users, with this particular product supported by a 510-K clearance. But not at other clinical data otherwise and on the Open AtriClip side of our business just would reiterate that we drove growth of 15.4% for the quarter and feel really good about those results.
Suraj Kalia: Thank you.
Operator: Thank you. I am showing no further questions at this time. I would now like to turn it back to Mike Carrel, President and Chief Executive Officer for closing remarks.
Mike Carrel: Great. Thank you again everyone for joining us on the call today. Another great quarter for AtriCure and enjoyed the question-and-answer session here. Everybody have a great evening. Bye now.
Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.